# US 2021/0261673 A1 · Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261673 A1
- Document ID: US20210261673A1
- Status: Published application
- Kind: A1
- Application number: 17/181,829
- Filed: 2021-02-22
- Published: 2021-08-26
- Earliest claimed: 2016-09-27
- Assignees: Fresenius Kabi Deutschland GmbH
- Applicants: Fresenius Kabi Deutschland GmbH
- Inventors: Alessandra DEL RIO; Carmela SABINA
- Web page: https://patentgrep.com/patent/US20210261673A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of an antibody directed to Interleukin-6 receptor, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.

## Claims

### Claim 1

A liquid pharmaceutical composition comprising:
(a) an anti-IL-6 receptor (anti-IL-6R) antibody;
(b) an histidine buffer;
(c) a polyol;
(d) a free amino acid;
(e) a surfactant;
(f) water for injection; and
(g) optionally a salt.
wherein the composition has a pH between 5.5 and 7.5.

### Claim 2 (depends on 1)

The liquid pharmaceutical according to claim 1, wherein the composition has a pH between 6.0 and 6.5.

### Claim 3 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the polyol is mannitol.

### Claim 4 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the free amino acid is methionine.

### Claim 5 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the surfactant is a polysorbate.

### Claim 6 (depends on 5)

The liquid pharmaceutical composition as claimed in claim 5, wherein the polysorbate is polysorbate 80.

### Claim 7 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the optional salt is sodium chloride.

### Claim 8 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the anti-IL6R antibody is selected from the group consisting of tocilizumab, sapelizumab, vobarilizumab or sarilumab.

### Claim 9 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the composition comprises:
15 to 200 mg/ml of anti-IL-6R;
10 and 25 mM histidine (or histidine buffer system);
190 to 210 mM mannitol;
0.4 to 0.6 mM methionine;
0.4 to 0.9 mM polysorbate 80;
water (for injection);
75 to 125 mM sodium chloride.

### Claim 10 (depends on 1)

A drug delivery device comprising a liquid pharmaceutical composition as claimed in claim 1.

### Claim 11 (depends on 1)

A liquid pharmaceutical composition as claimed in claim 1 for use in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, Giant cell arteritis or systemic sclerosis.
